EGFR and non-small cell lung carcinoma: Based on the results of the latest phase III trials [8,9] gefitinib, an EGFR tyrosine kinase inhibitor, has been approved in Europe for first line treatment of adult patients with locally advanced or metastatic NSCLC carrying activating EGFR somatic mutations.